查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1769681

2025年非病毒药物传输系统全球市场报告

Non-Viral Drug Delivery Systems Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计非病毒药物输送系统市场规模将在未来几年快速成长，到2029年将达到167.2亿美元，复合年增长率为14.2%。预测期内的成长动力包括标靶治疗的普及、药物传递创新投资的增加、对非侵入性治疗方法的日益关注、人工智慧的增强整合以及对缓释性日益增长的需求。预计这段时期的主要趋势包括奈米载体技术的进步、下一代生医材料的开发、mRNA输送系统的创新、智慧药物传输设备的整合以及基因编辑传输技术的改进。

个人化医疗需求的不断增长预计将推动非病毒药物输送系统市场的成长。个人化医疗是一种根据个人基因特征、生活方式和环境因素量身定制的治疗方法。这种不断增长的需求是由更有效的治疗方法的可能性所驱动的，这些方法可以解决每个患者疾病的根本原因。非病毒系统透过将药物和基因安全地输送到细胞来支持个人化医疗，从而最大限度地降低风险并提高治疗的精准度。例如，2024 年 2 月，美国非营利组织个人化医疗联盟报告称，FDA 在 2023 年核准了16 种针对罕见疾病患者的新型个人化治疗方法，高于 2022 年的 6 种。因此，对个人化医疗日益增长的偏好正在促进非病毒药物输送系统市场的扩张。

非病毒药物递送系统市场的关键参与者正专注于使用先进技术，例如预先优化的可电离脂质混合系统，以促进基于 RNA 的治疗方法的开发和市场发展。这种配方技术可以将 RNA 分子有效地封装在脂质奈米颗粒中，以确保稳定性、有效载荷保护和靶向基因递送。例如，2024 年 9 月，美国生物技术公司 Cytiva 宣布推出一款与其 NanoAssemblr Ignite 和 Ignite+ 平台相容的 RNA 递送 LNP套件。该系统采用即用型可电离脂质混合物，可快速进行 RNA 有效载荷筛检和递送检验，特别适用于感染疾病开发。它与自动化微流体平台集成，支援使用 GMP 级材料进行可扩展製造，并提供协议和概念验证数据，以指导使用者从药物发现到临床试验。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球非病毒药物传递系统：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球非病毒药物传输系统市场：成长率分析
  • 全球非病毒药物传输系统市场表现：规模与成长，2019-2024
  • 全球非病毒药物传输系统市场预测：规模与成长，2024-2029 年，2034 年
  • 全球非病毒药物传递系统：总目标市场（TAM）

第六章市场区隔

  • 全球非病毒药物输送系统市场（依输送分子类型划分）现况及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 生物製药
  • 小分子
  • 全球非病毒药物输送系统市场（依生物製药类型划分）现况及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 核糖核酸（RNA）
  • 去氧核糖核酸（DNA）
  • 蛋白质或胜肽
  • 抗体
  • 全球非病毒药物传输系统市场（依最终使用者、绩效及预测），2019-2024 年、2024-2029 年及 2034 年
  • 製药和生物技术公司
  • 学术研究所
  • 合约开发和製造组织（CDMO）
  • 医院和诊所
  • 全球非病毒药物传递系统市场，依生技药品类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 胜肽
  • 蛋白质
  • 单株抗体
  • 基于RNA的疗法
  • DNA治疗方法
  • 全球非病毒药物传递系统市场，小分子细分，按类型、绩效和预测，2019-2024 年、2024-2029 年、2034 年
  • 化疗药物
  • 抗发炎药物
  • 抗病毒药物
  • 抗生素
  • 荷尔蒙药物

第七章 区域和国家分析

  • 全球非病毒药物输送系统市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球非病毒药物输送系统市场：依国家/地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 非病毒药物传输系统市场：竞争格局
  • 非病毒药物传输系统市场：公司简介
    • Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
    • Cytiva Overview, Products and Services, Strategy and Financial Analysis
    • Arcturus Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • CureVac NV Overview, Products and Services, Strategy and Financial Analysis
    • PolyPid Ltd Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Ethris GmbH
  • Entos Pharmaceuticals Inc.
  • Liquidia Technologies Inc.
  • ReCode Therapeutics Inc.
  • Enable Injections Inc.
  • GenEdit Inc.
  • N4 Pharma Plc
  • Hopewell Therapeutics Inc.
  • Tiba Biotech LLC
  • Vesigen Therapeutics Inc.
  • Carmine Therapeutics Inc.
  • Evox Therapeutics Ltd
  • InnoCore Pharmaceuticals BV
  • Nanomerics Ltd
  • DelSiTech Ltd

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年非病毒药物输送系统市场：提供新机会的国家
  • 2029年非病毒药物输送系统市场：细分市场带来新机会
  • 2029年非病毒药物传输系统市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r35996

Non-viral drug delivery systems are methods used to administer therapeutic agents into the body without relying on viral vectors. These systems utilize various physical, chemical, or mechanical approaches-such as nanoparticles, liposomes, or polymer-based carriers-to effectively transport drugs to specific target areas. Their primary goal is to minimize the risks commonly associated with viral delivery methods, including immune responses and insertional mutagenesis. This strategy improves the overall efficacy of treatments while enhancing patient safety for a wide range of medical conditions.

Non-viral drug delivery systems are primarily used to deliver two main categories of molecules: biologics and small molecules. Biologics are therapeutic agents derived from living organisms and include proteins, peptides, monoclonal antibodies, as well as nucleic acid-based treatments like RNA and DNA. The biologics delivered using these systems include ribonucleic acid (RNA), deoxyribonucleic acid (DNA), proteins or peptides, and antibodies. The major end users of these systems are pharmaceutical and biotechnology companies, academic and research institutions, contract development and manufacturing organizations (CDMOs), and hospitals and clinics.

The non-viral drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides non-viral drug delivery systems market statistics, including the non-viral drug delivery systems industry global market size, regional shares, competitors with the non-viral drug delivery systems market share, detailed non-viral drug delivery systems market segments, market trends, and opportunities, and any further data you may need to thrive in the non-viral drug delivery systems industry. This non-viral drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-viral drug delivery systems market size has grown rapidly in recent years. It will grow from $8.60 billion in 2024 to $9.84 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth during the historical period is due to various drivers such as the increasing demand for safer gene therapy options, advancements in nanotechnology, a higher prevalence of chronic diseases, a stronger focus on personalized medicine, and enhanced regulatory backing for non-viral platforms.

The non-viral drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $16.72 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. Growth in the forecast period will be driven by the increasing adoption of targeted therapies, greater investment in drug delivery innovation, rising interest in non-invasive treatment methods, enhanced integration of artificial intelligence, and the growing need for sustained-release drug formulations. Key trends anticipated during this period include progress in nanocarrier technologies, development of next-generation biomaterials, innovations in mRNA delivery systems, incorporation of smart drug delivery devices, and improvements in gene editing delivery techniques.

The rising demand for personalized medicines is anticipated to drive the growth of the non-viral drug delivery systems market. Personalized medicine is a treatment approach tailored to an individual's genetic profile, lifestyle, and environmental factors. This growing demand is fueled by the potential for more effective treatments that address the root causes of disease in each patient. Non-viral systems support personalized medicine by delivering drugs or genes safely to cells, thereby minimizing risks and enhancing treatment accuracy. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, up from six approvals in 2022. As a result, the increasing preference for personalized medicines is contributing to the expansion of the non-viral drug delivery systems market.

Key companies in the non-viral drug delivery system market are emphasizing the use of advanced technologies, such as pre-optimized ionizable lipid mix systems, to facilitate the development and delivery of RNA-based therapies. This formulation technology allows RNA molecules to be efficiently encapsulated within lipid nanoparticles, ensuring stability, payload protection, and targeted gene delivery. For instance, in September 2024, Cytiva, a U.S.-based biotechnology firm, introduced an RNA delivery LNP kit that is compatible with its NanoAssemblr Ignite and Ignite+ platforms. The system features a ready-to-use ionizable lipid mix that enables swift RNA payload screening and validation for delivery, particularly useful in vaccine development for infectious diseases. It integrates with automated microfluidic platforms, supports scalable manufacturing using GMP-grade materials, and provides protocols and proof-of-concept data to guide users from discovery through clinical trials.

In September 2023, SOHM Inc., a U.S.-based pharmaceutical firm, acquired ABBIE from CGA 369 for $10 million to enhance its non-viral gene-editing capabilities. This acquisition bolsters SOHM's ability to deliver large genetic payloads through integrase-based, non-viral platforms. ABBIE is being developed for off-the-shelf gene-editing kits, with plans for commercialization in 2024 and human trials expected by the end of 2025. CGA 369, also a U.S.-based biotechnology company, focuses on non-viral, integrase-driven gene-editing and genetic delivery solutions.

Major players in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, and Curapath Inc.

North America was the largest region in the non-viral drug delivery systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-viral drug delivery systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-viral drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral drug delivery systems market consists of sales of exosomes, cell-penetrating peptides, and nanocrystals. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Drug Delivery Systems Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-viral drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-viral drug delivery systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-viral drug delivery systems market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type Of Molecule Delivered: Biologics; Small Molecules
  • 2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA); Deoxyribonucleic Acid (DNA); Proteins or Peptides; Antibodies
  • 3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Development And Manufacturing Organizations (CDMOs); Hospitals And Clinics
  • Subsegments:
  • 1) By Biologics: Peptides; Proteins; Monoclonal Antibodies; RNA-based Therapeutics; DNA-based Therapies
  • 2) By Small Molecules: Chemotherapeutics; Anti-inflammatories; Antivirals; Antibiotics; Hormonal Drugs
  • Companies Mentioned: Evonik Industries AG; Cytiva; Arcturus Therapeutics Holdings Inc.; CureVac N.V.; PolyPid Ltd
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Viral Drug Delivery Systems Market Characteristics

3. Non-Viral Drug Delivery Systems Market Trends And Strategies

4. Non-Viral Drug Delivery Systems Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Non-Viral Drug Delivery Systems Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Non-Viral Drug Delivery Systems PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Non-Viral Drug Delivery Systems Market Growth Rate Analysis
  • 5.4. Global Non-Viral Drug Delivery Systems Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Non-Viral Drug Delivery Systems Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Non-Viral Drug Delivery Systems Total Addressable Market (TAM)

6. Non-Viral Drug Delivery Systems Market Segmentation

  • 6.1. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biologics
  • Small Molecules
  • 6.2. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ribonucleic Acid (RNA)
  • Deoxyribonucleic Acid (DNA)
  • Proteins Or Peptides
  • Antibodies
  • 6.3. Global Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pharmaceutical And Biotechnology Companies
  • Academic And Research Institutes
  • Contract Development And Manufacturing Organizations (CDMOs)
  • Hospitals And Clinics
  • 6.4. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Peptides
  • Proteins
  • Monoclonal antibodies
  • RNA-based therapeutics
  • DNA-based therapies
  • 6.5. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chemotherapeutics
  • Anti-inflammatories
  • Antivirals
  • Antibiotics
  • Hormonal drugs

7. Non-Viral Drug Delivery Systems Market Regional And Country Analysis

  • 7.1. Global Non-Viral Drug Delivery Systems Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Non-Viral Drug Delivery Systems Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Viral Drug Delivery Systems Market

  • 8.1. Asia-Pacific Non-Viral Drug Delivery Systems Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Viral Drug Delivery Systems Market

  • 9.1. China Non-Viral Drug Delivery Systems Market Overview
  • 9.2. China Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Viral Drug Delivery Systems Market

  • 10.1. India Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Viral Drug Delivery Systems Market

  • 11.1. Japan Non-Viral Drug Delivery Systems Market Overview
  • 11.2. Japan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Viral Drug Delivery Systems Market

  • 12.1. Australia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Viral Drug Delivery Systems Market

  • 13.1. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Viral Drug Delivery Systems Market

  • 14.1. South Korea Non-Viral Drug Delivery Systems Market Overview
  • 14.2. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Viral Drug Delivery Systems Market

  • 15.1. Western Europe Non-Viral Drug Delivery Systems Market Overview
  • 15.2. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Viral Drug Delivery Systems Market

  • 16.1. UK Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Viral Drug Delivery Systems Market

  • 17.1. Germany Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Viral Drug Delivery Systems Market

  • 18.1. France Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Viral Drug Delivery Systems Market

  • 19.1. Italy Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Viral Drug Delivery Systems Market

  • 20.1. Spain Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Viral Drug Delivery Systems Market

  • 21.1. Eastern Europe Non-Viral Drug Delivery Systems Market Overview
  • 21.2. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Viral Drug Delivery Systems Market

  • 22.1. Russia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Viral Drug Delivery Systems Market

  • 23.1. North America Non-Viral Drug Delivery Systems Market Overview
  • 23.2. North America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Viral Drug Delivery Systems Market

  • 24.1. USA Non-Viral Drug Delivery Systems Market Overview
  • 24.2. USA Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Viral Drug Delivery Systems Market

  • 25.1. Canada Non-Viral Drug Delivery Systems Market Overview
  • 25.2. Canada Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Viral Drug Delivery Systems Market

  • 26.1. South America Non-Viral Drug Delivery Systems Market Overview
  • 26.2. South America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Viral Drug Delivery Systems Market

  • 27.1. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Viral Drug Delivery Systems Market

  • 28.1. Middle East Non-Viral Drug Delivery Systems Market Overview
  • 28.2. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Viral Drug Delivery Systems Market

  • 29.1. Africa Non-Viral Drug Delivery Systems Market Overview
  • 29.2. Africa Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Viral Drug Delivery Systems Market Competitive Landscape And Company Profiles

  • 30.1. Non-Viral Drug Delivery Systems Market Competitive Landscape
  • 30.2. Non-Viral Drug Delivery Systems Market Company Profiles
    • 30.2.1. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Cytiva Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Arcturus Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. CureVac N.V. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. PolyPid Ltd Overview, Products and Services, Strategy and Financial Analysis

31. Non-Viral Drug Delivery Systems Market Other Major And Innovative Companies

  • 31.1. Ethris GmbH
  • 31.2. Entos Pharmaceuticals Inc.
  • 31.3. Liquidia Technologies Inc.
  • 31.4. ReCode Therapeutics Inc.
  • 31.5. Enable Injections Inc.
  • 31.6. GenEdit Inc.
  • 31.7. N4 Pharma Plc
  • 31.8. Hopewell Therapeutics Inc.
  • 31.9. Tiba Biotech LLC
  • 31.10. Vesigen Therapeutics Inc.
  • 31.11. Carmine Therapeutics Inc.
  • 31.12. Evox Therapeutics Ltd
  • 31.13. InnoCore Pharmaceuticals BV
  • 31.14. Nanomerics Ltd
  • 31.15. DelSiTech Ltd

32. Global Non-Viral Drug Delivery Systems Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Viral Drug Delivery Systems Market

34. Recent Developments In The Non-Viral Drug Delivery Systems Market

35. Non-Viral Drug Delivery Systems Market High Potential Countries, Segments and Strategies

  • 35.1 Non-Viral Drug Delivery Systems Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Non-Viral Drug Delivery Systems Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Non-Viral Drug Delivery Systems Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer